Amneal introduces generic Exelon Patch
Amneal Pharmaceuticals has launched its generic Exelon Patch (rivastigmine transdermal system), in 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours dosage strengths. The product is a generic of Novartis' branded product and is used to treat symptoms of mild to moderately severe Alzheimer's disease.
Amneal received the Food and Drug Administration’s approval of its rivastigmine transdermal system in January.
"We are pleased to have received approval on and launched the company's first transdermal product, which demonstrates our commitment to develop and bring to market complex generic products," Amneal president and CEO Rob Stewart said. "Our diverse pipeline of approximately 220 products is expected to deliver additional complex product approvals this year and help us achieve our goal of launching up to 50 generic products in 2019."
Rivastigmine transdermal system had a market value of approximately $214 million for the 12 months ended January 2019, according to IQVIA data.
Amneal received the Food and Drug Administration’s approval of its rivastigmine transdermal system in January.
"We are pleased to have received approval on and launched the company's first transdermal product, which demonstrates our commitment to develop and bring to market complex generic products," Amneal president and CEO Rob Stewart said. "Our diverse pipeline of approximately 220 products is expected to deliver additional complex product approvals this year and help us achieve our goal of launching up to 50 generic products in 2019."
Rivastigmine transdermal system had a market value of approximately $214 million for the 12 months ended January 2019, according to IQVIA data.